Literature DB >> 25262067

The use of prognostic factors in inflammatory bowel diseases.

Thomas Billiet1, Marc Ferrante, Gert Van Assche.   

Abstract

The disease spectrum and natural course of Crohn's disease and ulcerative colitis are highly variable. The majority of Crohn's disease patients will require surgery at a certain stage in their disease compared to only a fraction of the ulcerative colitis patients. Similarly, some patients are destined to experience an indolent disease course while others will require early intensive therapy. Ideally, these subtypes of patients should be identified as early as possible with the help of reliable prognostic factors in order to guide personalized therapeutic decisions. In this review, the authors focused on the most relevant reports on the use of different prognostic factors to predict disease course, postoperative recurrence and response to therapy in patients with inflammatory bowel disease. The last 15 years have seen a wealth of novel genetic and serological markers of disease severity. Nevertheless, none of these markers have proven to be superior to careful clinical phenotyping and endoscopic features early in the disease course. Future attempts should apply an integrated approach that unites clinical, serological and (epi)genetic information with environmental influences, with a clear focus on the microbiome to ultimately identify molecular-based and clinically relevant subgroups.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25262067     DOI: 10.1007/s11894-014-0416-y

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  137 in total

1.  Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors.

Authors:  Tibor Hlavaty; Marc Ferrante; Liesbet Henckaerts; Marie Pierik; Paul Rutgeerts; Severine Vermeire
Journal:  Inflamm Bowel Dis       Date:  2007-04       Impact factor: 5.325

2.  Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease.

Authors:  Andrew Ippoliti; Shane Devlin; Ling Mei; Huiying Yang; Konstantinos A Papadakis; Eric A Vasiliauskas; Dermot P B McGovern; Maria T Abreu; Gil Melmed; Omid Shaye; Pedram Enayati; Gary Chen; Jennifer Choi; Kent Taylor; Carol J Landers; Jerome I Rotter; Stephan R Targan
Journal:  Inflamm Bowel Dis       Date:  2010-08       Impact factor: 5.325

3.  Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease.

Authors:  Iris Dotan; Sigal Fishman; Yaara Dgani; Mikael Schwartz; Amir Karban; Aaron Lerner; Oori Weishauss; Larissa Spector; Avi Shtevi; Rom T Altstock; Nir Dotan; Zamir Halpern
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

4.  Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease.

Authors:  J Satsangi; K I Welsh; M Bunce; C Julier; J M Farrant; J I Bell; D P Jewell
Journal:  Lancet       Date:  1996-05-04       Impact factor: 79.321

5.  Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression.

Authors:  Marla C Dubinsky; Ying-Chao Lin; Debra Dutridge; Yoana Picornell; Carol J Landers; Sharmayne Farrior; Iwona Wrobel; Antonio Quiros; Eric A Vasiliauskas; Bruce Grill; David Israel; Ron Bahar; Dennis Christie; Ghassan Wahbeh; Gary Silber; Saied Dallazadeh; Praful Shah; Danny Thomas; Drew Kelts; Robert M Hershberg; Charles O Elson; Stephan R Targan; Kent D Taylor; Jerome I Rotter; Huiying Yang
Journal:  Am J Gastroenterol       Date:  2006-02       Impact factor: 10.864

6.  Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis.

Authors:  Garrett C Zella; Elizabeth J Hait; Tiffany Glavan; Dirk Gevers; Doyle V Ward; Christopher L Kitts; Joshua R Korzenik
Journal:  Inflamm Bowel Dis       Date:  2010-09-15       Impact factor: 5.325

Review 7.  Associations between NOD2/CARD15 genotype and phenotype in Crohn's disease--Are we there yet?

Authors:  Graham Radford-Smith; Nirmala Pandeya
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

8.  Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor?

Authors:  Carmen B Meier; Refaat A Hegazi; James Aisenberg; Peter E Legnani; Naris Nilubol; Gena M Cobrin; Richard H Duerr; Stephen R Gorfine; Joel J Bauer; David B Sachar; Scott E Plevy
Journal:  Inflamm Bowel Dis       Date:  2005-11       Impact factor: 5.325

9.  Phenotype-genotype profiles in Crohn's disease predicted by genetic markers in autophagy-related genes (GOIA study II).

Authors:  Cecília Durães; José C Machado; Francisco Portela; Susana Rodrigues; Paula Lago; Marília Cravo; Paula Ministro; Margarida Marques; Isabelle Cremers; João Freitas; José Cotter; Lurdes Tavares; Leopoldo Matos; Isabel Medeiros; Rui Sousa; Jaime Ramos; João Deus; Paulo Caldeira; Cristina Chagas; Maria A Duarte; Raquel Gonçalves; Rui Loureiro; Luísa Barros; Isabel Bastos; Eugénia Cancela; Mário C Moraes; Maria J Moreira; Ana I Vieira; Fernando Magro
Journal:  Inflamm Bowel Dis       Date:  2013-02       Impact factor: 5.325

10.  Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis.

Authors:  James C Lee; Paul A Lyons; Eoin F McKinney; John M Sowerby; Edward J Carr; Francesca Bredin; Hannah M Rickman; Huzefa Ratlamwala; Alexander Hatton; Tim F Rayner; Miles Parkes; Kenneth G C Smith
Journal:  J Clin Invest       Date:  2011-09-26       Impact factor: 14.808

View more
  6 in total

Review 1.  The Role of Early Biologic Therapy in Inflammatory Bowel Disease.

Authors:  Dana Rachel Berg; Jean-Frederic Colombel; Ryan Ungaro
Journal:  Inflamm Bowel Dis       Date:  2019-11-14       Impact factor: 5.325

2.  Predictive parameters for the clinical course of Crohn's disease: development of a simple and reliable risk model.

Authors:  Andreas Stallmach; Bernd Bokemeyer; Ulf Helwig; Andreas Lügering; Niels Teich; Imma Fischer; Stefan Rath; Dorothee Lang; Carsten Schmidt
Journal:  Int J Colorectal Dis       Date:  2019-08-24       Impact factor: 2.571

3.  Contribution of susceptibility variants at FCGR2A and 13q12 to the risk of relapse among Japanese patients with ulcerative colitis.

Authors:  Kouichi Asano; Motohiro Esaki; Junji Umeno; Atsushi Hirano; Yuji Maehata; Tomohiko Moriyama; Shotaro Nakamura; Takayuki Matsumoto; Takanari Kitazono
Journal:  J Gastroenterol       Date:  2015-03-19       Impact factor: 7.527

4.  Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011-2014: A Nationwide Population-Based Study.

Authors:  Yoon Suk Jung; Minkyung Han; Won Ho Kim; Sohee Park; Jae Hee Cheon
Journal:  Dig Dis Sci       Date:  2017-06-07       Impact factor: 3.199

5.  Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases.

Authors:  Joana Torres; Flavio Caprioli; Konstantinos H Katsanos; Triana Lobatón; Dejan Micic; Marco Zerôncio; Gert Van Assche; James C Lee; James O Lindsay; David T Rubin; Remo Panaccione; Jean-Frédéric Colombel
Journal:  J Crohns Colitis       Date:  2016-06-09       Impact factor: 9.071

6.  Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn's disease.

Authors:  Ioannis Papaconstantinou; Christina Kapizioni; Evangelia Legaki; Elena Xourgia; George Karamanolis; Antonios Gklavas; Maria Gazouli
Journal:  World J Gastrointest Pharmacol Ther       Date:  2017-11-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.